Attenuated efficacy of the non-steroidal aromatase inhibitor anastrozole has also been reported in premenopausal obese women with early breast cancer treated with ovarian suppression by goserelin in the ABCSG 12 trial [92]. The gene discussed is CYP19A1; the disease is breast carcinoma.